Table 3 Mean estimates of each QL indicator from the (a) IBCSG Core Form and (b) trial-specific module by treatment group at months 0, 3, 6, 9, 12, and 18 months from randomisationa

From: Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer

  Months from randomisation
  0 3 6 9 12 18
QL SD-CT DI-EC P -value SD-CT DI-EC P -value SD-CT DI-EC P -value SD-CT DI-EC P -value SD-CT DI-EC P -value SD-CT DI-EC P -value
(a)
Physical well-being 84±2 87±2 0.24 73±3 52±4 <0.01 75±3 84±3 0.01 88±2 87±2 0.76 89±2 89±2 0.90 88±2 90±2 0.30
Mood 74±3 74±3 0.95 74±3 64±4 0.01 76±3 84±3 0.02 85±2 83±2 0.51 86±2 87±2 0.71 88±2 89±2 0.52
Tiredness 76±3 78±3 0.42 56±4 46±5 0.05 59±4 73±4 <0.01 69±3 75±3 0.12 76±3 76±3 0.94 74±3 81±3 0.03
Appetite 89±2 90±2 0.60 81±3 58±4 <0.01 85±2 88±2 0.27 92±2 92±2 0.84 94±2 93±2 0.97 94±1 94±2 0.94
Hot flushes 93±2 94±2 0.65 84±3 90±3 0.05 76±4 79±4 0.60 68±4 71±4 0.44 68±4 77±4 0.05 63±5 70±5 0.16
Nausea/vomiting 96±1 98±1 0.23 74±3 74±3 0.83 84±2 96±1 <0.01 98±1 97±1 0.46 97±1 98±1 0.56 98±1 98±1 0.71
Coping effort 60±4 61±4 0.94 60±4 51±4 0.06 62±4 76±3 <0.01 73±3 78±3 0.12 77±3 78±3 0.83 78±3 83±3 0.09
Feel supported 97±1 97±1 0.87 93±1 96±1 0.04 93±1 96±1 0.07 94±1 94±1 0.91 93±1 94±1 0.40 93±1 95±1 0.18
Arm restriction 71±3 71±3 0.84 83±2 81±3 0.49 85±2 82±3 0.44 83±2 81±3 0.49 80±3 82±3 0.51 84±2 83±3 0.67
Subjective health 75±2 73±3 0.65 65±3 61±4 0.30 67±3 79±3 <0.01 75±3 83±2 0.01 79±2 84±2 0.06 80±2 86±2 0.01
(b)
Hair loss 94±2 96±1 0.24 36±5 34±6 0.79 83±3 85±3 0.63 94±2 93±2 0.63       
Numbness 92±2 93±1 0.63 88±2 90±2 0.43 89±2 88±2 0.81 91±2 87±2 0.16       
Thoughts 60±3 58±4 0.66 63±3 53±4 0.05 70±3 84±3 <0.01 89±2 89±2 0.83       
Sexual interest 81±3 77±3 0.38 64±4 62±4 0.76 63±4 80±3 <0.01 79±3 83±3 0.28       
Sore mouth 98±1 98±1 0.70 85±2 65±4 <0.01 90±2 96±1 0.01 97±1 98±1 0.58       
Pain 90±2 91±2 0.74 88±2 84±2 0.11 88±2 91±2 0.34 90±2 92±2 0.44       
Treatment burden 78±2 76±3 0.59 64±3 50±4 <0.01 68±3 81±3 <0.01 86±2 82±3 0.24       
Daily activity 74±2 74±3 0.99 68±3 52±4 <0.01 73±3 79±3 0.06 82±2 84±2 0.49       
  1. Abbreviations: QL=quality of life; DI-EC=dose-intensive epirubicin cyclophosphamide; SD-CT=standard dose chemotherapy (ACx4-CMFx3). Higher scores indicate a better condition for all indicators.
  2. Estimates were obtained from a linear mixed-effects model adjusted for patients’ age, culture, and baseline score.